scholarly journals Identification of a High-Risk Group for Brain Metastases in Non-Small Cell Lung Cancer Patients.

2021 ◽  
Author(s):  
Bernardo Cacho-Díaz ◽  
D. Cuapaténcatl Laura ◽  
Jose Antonio Rodriguez ◽  
Ytel Jazmin Garcilazo-Reyes ◽  
Nancy Reynoso-Noverón ◽  
...  
Keyword(s):  
Lung Cancer ◽  
High Risk ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Risk Group ◽  
High Risk Group ◽  
Small Cell ◽  
Multivariate Model ◽  
Small Cell Lung

Abstract Purpose: Identification of a truly high-risk group of brain metastases (BM) in patients with non-small cell lung cancer (NSCLC) could lead to early interventions and probably better prognosis. The objective of the study was to identify this group by generating a multivariable model with recognized and accessible risk factors.Methods: A retrospective cohort from patients seen at a single center during 2010-2020, was divided into a training (TD) and validation (VD) datasets, associations with BM were measured in the TD with logit, variables significantly associated were used to generate a multivariate model. Model´s performance was measured by 10-Fold cross validation of the TD and in the VD with the AUC/C-statistic, Akaike information index, and Press´s Q precision test.Results: From 570 patients with NSCLC with complete records a TD and VD were formed, no significant differences were found amid both datasets. Variables associated with BM in the multivariate logit analyses were age [P 0.021, OR 0.97 (95%CI 0.94-0.99)]; male gender [P 0.010, OR 2.44 (95%CI 1.24-4.82)]; mutational status [P 0.03, OR 2.1 (95%CI 1.07-4.12); and carcinoembryonic antigen levels [P 0.002, OR 1.002 (95%CI 1.001 – 1.003). BM were diagnosed in 23% of the whole cohort. Stratification into low, medium, or high-risk groups after simplification of the model, displayed a frequency of BM in the VD of 8%, 16% and 40% respectively (P 0.027).Conclusion: A multivariate model comprising age, gender, CEA, and mutation status allowed the identification of a truly high-risk group of BM in NSCLC patients.

scholarly journals Identification of a high-risk group for brain metastases in non-small cell lung cancer patients

2021 ◽  
Author(s):  
Bernardo Cacho-Díaz ◽  
Laura Denisse Cuapaténcatl ◽  
Jose Antonio Rodríguez ◽  
Ytel Jazmin Garcilazo-Reyes ◽  
Nancy Reynoso-Noverón ◽  
...  
Keyword(s):  
Lung Cancer ◽  
High Risk ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Risk Group ◽  
High Risk Group ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients

scholarly journals P14.97 High risk of venous thromboembolism in patients with brain metastases from non-small cell lung cancer

2019 ◽  
Vol 21 (Supplement_3) ◽  
pp. iii91-iii91
Author(s):  
P Mir Seyed Nazari ◽  
C Ay ◽  
A Steindl ◽  
B Gatterbauer ◽  
J M Frischer ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Venous Thromboembolism ◽  
High Risk ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Carcinoma ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Nsclc Patients

Abstract BACKGROUND Venous thromboembolism (VTE) is a common complication in patients with cancer. In general, patients with metastatic disease are at highest risk. Lung cancer belong to those tumor entities with a particularly high risk of VTE, ranging between 3–13.8%. However, little is known about the VTE rate in lung cancer patients with brain metastases. MATERIAL AND METHODS Our study was conducted in the framework of the Vienna Brain Metastasis Registry. Clinical data and VTE events during the course of the disease were recorded via retrospective chart review. In this analysis, non-small cell lung cancer (NSCLC) patients with a resection of brain metastases at the Medical University of Vienna between 2006 and 2010 were included. RESULTS In total, 69 NSCLC patients with brain metastases were analyzed. Overall, 69.6% (48/69) patients had an adenocarcinoma, 13% (9/69) a squamous cell carcinoma, 8.7% (6/69) a large cell carcinoma and 8.7% (6/69) other primary tumor histologies. After cancer diagnosis, 20.3% (14/69) patients developed VTE during the course of the disease. Of those, 85.7% (12/14) thromboembolic events occurred after the diagnosis of brain metastases. CONCLUSION Based on our data, patients with brain metastases from NSCLC have a very high VTE risk. Further investigations are needed in order to identify patients with distinct VTE risk profiles. Patients at high risk might potentially benefit from primary thromboprophylaxis over the high risk of intracerebral bleeding.

scholarly journals Five-fraction stereotactic radiosurgery (SRS) for single inoperable high-risk non-small cell lung cancer (NSCLC) brain metastases

2015 ◽  
Vol 10 (1) ◽  
Author(s):  
Jonathan W. Lischalk ◽  
Eric Oermann ◽  
Sean P. Collins ◽  
Mani N. Nair ◽  
Vikram V. Nayar ◽  
...  
Keyword(s):  
Lung Cancer ◽  
High Risk ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Stereotactic Radiosurgery ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Premalignant Changes in the Bronchial Epithelium Are Prognostic Factors of Distant Metastasis in Non-Small Cell Lung Cancer Patients

2021 ◽  
Vol 11 ◽  
Author(s):  
Olga V. Pankova ◽  
Liubov A. Tashireva ◽  
Evgeny O. Rodionov ◽  
Sergey V. Miller ◽  
Sergey A. Tuzikov ◽  
...  
Keyword(s):  
Lung Cancer ◽  
High Risk ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Distant Metastasis ◽  
Risk Group ◽  
Morphological Changes ◽  
Distant Metastases ◽  
Small Cell ◽  
Small Cell Lung

BackgroundThe study assessed the possibility of dividing patients into groups based on the assessment of morphological changes in the epithelium of small-caliber bronchi located near the primary tumor in order to predict high and low risks of distant metastasis of non-small cell lung cancer.MethodsIn 171 patients with non-small cell lung cancer (T1-4N0-3M0) in small-caliber bronchi taken at a distance of 3–5 cm from the tumor, various variants of morphological changes in the bronchial epithelium (basal cell hyperplasia (BCH), squamous cell metaplasia (SM), and dysplasia (D)) were assessed. Long-term results of treatment, namely, distant metastasis, were assessed after 2 and 5 years.ResultsDuring the follow-up period, distant metastases were found in 35.1% (60/171) of patients. Most often, they were observed in patients of the high-risk group: BCH+SM−D− (51.6%, 40/95) and BCH−SM+D+ (54.4%, 6/11). Less often, distant metastases were observed in low-risk group patients: BCH+SM+D− (6.7%, 3/45) and BCH−SM−D− (10.0%, 2/20). Tumor size, grade, and stage were significant predictors of metastasis only in the high-risk group. The 5-year metastasis-free survival was better in the low-risk group of distant metastases.ConclusionsIsolated BCH or dysplasia in small bronchi distant from foci of tumor is associated with a high-risk distant metastasis and less 5-year metastasis-free survival.

scholarly journals Identification and Validation of an Immune and Ferroptosis-Combined Index for Non–Small Cell Lung Cancer

2021 ◽  
Vol 12 ◽  
Author(s):  
Yang Teng ◽  
Bo Wang ◽  
Desi Shang ◽  
Ning Yang
Keyword(s):  
Lung Cancer ◽  
High Risk ◽  
Small Cell Lung Cancer ◽  
Risk Score ◽  
Cell Lung Cancer ◽  
Risk Group ◽  
Risk Groups ◽  
Small Cell ◽  
Low Risk ◽  
Small Cell Lung

Background: Non–small cell lung cancer (NSCLC) is among the major health problems around the world. Reliable biomarkers for NSCLC are still needed in clinical practice. We aimed to develop a novel ferroptosis- and immune-based index for NSCLC.Methods: The training and testing datasets were obtained from TCGA and GEO databases, respectively. Immune- and ferroptosis-related genes were identified and used to establish a prognostic model. Then, the prognostic and therapeutic potential of the established index was evaluated.Results: Intimate interaction of immune genes with ferroptosis genes was observed. A total of 32 prognosis-related signatures were selected to develop a predictive model for NSCLC using LASSO Cox regression. Patients were classified into the high- and low-risk group based on the risk score. Patients in the low-risk group have better OS in contrast with that in the high-risk group in independent verification datasets. Besides, patients with a high risk score have shorter OS in all subgroups (T, N, and M0 subgroups) and pathological stages (stage I, II, and III). The risk score was positively associated with Immune Score, Stromal Score, and Ferroptosis Score in TCGA and GEO cohorts. A differential immune cell infiltration between the high-risk and the low-risk groups was also observed. Finally, we explored the significance of our model in tumor-related pathways, and different enrichment levels in the therapeutic pathway were observed between the high- and low-risk groups.Conclusion: The present study developed an immune and ferroptosis-combined index for the prognosis of NSCLC.

Sign in / Sign up

Export Citation Format

Share Document